Health Canada Suspends Sales Of Antipsychotic Thioridazine
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency decision to withdraw the drug answers concerns about cardiovascular risk; thioridazine to remain on U.S. market with existing “black box” warning.